Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

Jang, Jin‐Young; Han, Youngmin; Lee, Hongeun; Kim, Sun‐Whe; Kwon, Wooil; Lee, Kyung-Hun; Oh, Do‐Youn; Kyu Chie, Eui; Min Lee, Jeong; Seok Heo, Jin; Oh Park, Joon; Hoon Lim, Do; Hyun Kim, Seong; Park, Sang‐Jae; Jin Lee, Woo; Hwan Koh, Young; Seong Park, Joon; Sup Yoon, Dong; Jae Lee, Ik; Ho Choi, Seong

doi:10.1097/sla.0000000000002705

Public

Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

Published in Annals of Surgery • Feb 18, 2018

Authors:

Jin‐Young Jang

Youngmin Han

Hongeun Lee

Abstract

OBJECTIVE: This study was performed to determine whether neoadjuvant treatment increases survival in patients with BRPC. SUMMARY BACKGROUND DATA: Despite many promising retrospective data on the effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC), no high-level evidenc...

Subject

Medicine

Gemcitabine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!